Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 15/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925608 | 0.92 | CFD (0.39) | MCL1CFD | |
| SCHEMBL17026526 | 0.89 | SCN9A (0.40) | MCL1CFDTDP1HSD17B10LPAR1 | |
| SCHEMBL29781957 | 0.89 | SCN9A (0.40) | MCL1CFDTDP1HSD17B10LPAR1 | |
| SCHEMBL18549402 | 0.82 | CFD (0.39) | MCL1CFDLPAR1LPAR3 | |
| SCHEMBL18549387 | 0.81 | CFD (0.41) | CFD | |
| SCHEMBL18549439 | 0.81 | CFD (0.38) | MCL1CFDTDP1 | |
| SCHEMBL29781460 | 0.80 | CFD (0.41) | CFDHSD17B10ELANE | |
| SCHEMBL19208481 | 0.80 | CFD (0.41) | CFDHSD17B10ELANE | |
| SCHEMBL18549392 | 0.79 | MCL1 (0.38) | MCL1CFDHSD17B10LPAR1LPAR3 | |
| SCHEMBL15607641 | 0.78 | CFD (0.42) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | MCL1 1060/4885CFD 25/4885TDP1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.